Tous Actualités
Suivre
Abonner Zeltia Group

Zeltia Group

Zeltia: Report at 31 December 2005

Madrid (ots/PRNewswire)

Group:
  • Capital increase at Zeltia. The placement of 10.75 million new shares among qualified international investors raised 65 million euro
  • R&D expenditure up 24%
  • Net revenues in 2005: 72 million euro
  • Net cash position at 31 December 2005: 93 million euro net of short-term financial debt and 51 million euro net of total financial debt
PharmaMar:
  • Yondelis(R):
  • Phase III pivotal trial on ovarian cancer commenced
  • Recruitment for the pivotal randomised trial on soft-tissue sarcoma was completed
  • Aplidin(R):
  • Phase II studies on prostate and bladder cancer commenced
  • Combination studies with other chemotherapy agents commenced
  • Zalypsis(R), PharmaMar's fifth compound to reach clinical trials
  • PM02734 is PharmaMar's sixth compound to reach clinical trials
Xylazel:
  • Launched a full range of Xylazel-brand wood protecting paints and varnishes.
  • Conclusion of licensing and marketing agreement with ICI.
Isabel Lozano
    Chief Executive Officer
    PHARMAMAR, S.A.
    C/ Reyes, 1.
    Colmenar Viejo Madrid
    Telephone +34-91-846-60-00
    Catherine Moukheibir
    Head of Capital Market Strategy
    ZELTIA, S.A.
    José Abascal, 2. Madrid
    Telephone +34-91-444-45-00
    Ma Luisa de Francia
    Chief Financial Officer
    ZELTIA, S.A.
    José Abascal, 2. Madrid
    Telephone +34-91-444-45-00
For a copy of the full results, please refer to www.zeltia.com

Contact:

Isabel Lozano, Chief Executive Officer, PHARMAMAR, S.A., C/ Reyes,
1., Colmenar Viejo, Madrid, Telephone +34-91-846-60-00; Catherine
Moukheibir, Head of Capital Market Strategy, ZELTIA, S.A., José
Abascal, 2. Madrid, Telephone +34-91-444-45-00; Ma Luisa de Francia,
Chief Financial Officer, ZELTIA, S.A., José Abascal, 2. Madrid,
Telephone +34-91-444-45-00

Plus de actualités: Zeltia Group
Plus de actualités: Zeltia Group
  • 31.01.2006 – 08:30

    FDA Grants IND for PharmaMar's ZALYPSIS(r) to Enter Phase I Clinical Trials in US

    Madrid, Spain (ots/PRNewswire) - PharmaMar announced today that its Investigational New Drug application (IND)[1] has been accepted by the US Food and Drug Administration (FDA) for the clinical testing of Zalypsis(R) (PM00104/50), PharmaMar's novel marine anti-tumour agent. Zalypsis is already in Phase I clinical development in Europe, where three multicenter ...

  • 20.12.2005 – 08:25

    PharmaMar Confirms Intention to Submit MAA to EMEA for YONDELIS(R) in Soft Tissue Sarcoma

    Madrid (ots/PRNewswire) - - IDMC Recommends Adoption of 24hr Dosing in Pivotal Trial PharmaMar today announces that the independent data monitoring committee (IDMC) for the pivotal trial of YONDELIS(R) in Soft Tissue Sarcoma (STS) has reviewed data from a pre-planned interim analysis of the primary end-point, Time to Progression (TTP), which indicate that ...

  • 15.09.2005 – 08:30

    Aplidin(R) Commences Combination Trials

    Madrid (ots/PRNewswire) - - Further Steps in the Development of Aplidin(R) in Melanoma in First Line Therapy PharmaMar announces the initiation of a programme of combination studies with Aplidin(R) (plitidepsin), PharmaMar's novel marine-derived anti-tumour agent, originally isolated from the tunicate Aplidium albicans. Aplidin(R) in Combination with Dacarbazine (DTIC) The first study is a Phase I/II ...